Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
73 Results for "
type I TGF-
" in MedChemExpress (MCE) Product Catalog:
Products (73)
73 Results for "type I TGF-" in MCE Product Catalog:
144
144 Publications Verification
Target:
Research Areas:
A 83-01 is a potent inhibitor of TGF-β type I receptor ALK5 kinase, type I nodal receptor ALK4 and type I nodal receptor ALK7, with IC50s of 12 nM, 45 nM and 7.5 nM against the transcription induced by ALK5, ALK4 and ALK7, respectively .
144
144 Publications Verification
Target:
Research Areas:
A 83-01 sodium is a potent inhibitor of TGF-β type I receptor ALK5 kinase, ALK4 and ALK7, with IC50s of 12 nM, 45 nM and 7.5 nM against the transcription induced by ALK5, ALK4 and ALK7, respectively .
75
75 Cited Publications
Target:
Research Areas:
LY2109761 is an orally active, selective TGF-β receptor type I/II inhibitor with Kis of 38 nM and 300 nM, respectively.
74
Target:
Research Areas:
Galunisertib (LY2157299) is an oral and selective TGF-β receptor type I (TGF-βRI) kinase inhibitor with an IC50 of 56 nM.
25
25 Cited Publications
Target:
Research Areas:
SB-505124 is a selective inhibitor of TGF-β Receptor type I receptors (ALK4, ALK5, ALK7), with IC50s of 129 nM and 47 nM for ALK4, ALK5, respectively, but it does not inhibit ALK1, 2, 3, or 6.
25
25 Cited Publications
Target:
Research Areas:
SB-505124 hydrochloride is a selective inhibitor of TGF-β Receptor type I receptor (ALK4, ALK5, ALK7), with IC50s of 129 nM and 47 nM for ALK4, ALK5, respectively, but it does not inhibit ALK1, 2, 3, or 6.
23
23 Cited Publications
Synonyms: E-616452; SJN 2511
Target:
Research Areas:
RepSox (E-616452) is a potent and selective transforming growth factor-beta receptor I/activin like kinase 5 (TGF-β-RI/ALK5) inhibitor. RepSox inhibits ALK5 autophosphorylation with an IC50 value of 4 nM. RepSox can be used for the research of obesity and associated metabolic diseases such as type 2 diabetes .
22
22
22
Research Areas:
Cardiovascular Disease Infection Inflammation/Immunology Cancer
Halofuginone lactate (RU-19110 lactate), a Febrifugine derivative, is a competitive prolyl-tRNA synthetase inhibitor with a Ki of 18.3 nM . Halofuginone lactate is a specific inhibitor of type-I collagen synthesis and attenuates osteoarthritis (OA) by inhibition of TGF-β activity . Halofuginone lactate is also a potent pulmonary vasodilator by activating Kv channels and blocking voltage-gated, receptor-operated and store-operated Ca 2+ channels. Halofuginone lactate has anti-malaria, anti-inflammatory, anti-cancer, anti-fibrosis effects .
20
Halofuginone hydrochloride (RU-19110 hydrochloride), a Febrifugine derivative, is a competitive prolyl-tRNA synthetase inhibitor with a Ki of 18.3 nM . Halofuginone hydrochloride is a specific inhibitor of type-I collagen synthesis and attenuates osteoarthritis (OA) by inhibition of TGF-β activity . Halofuginone hydrochloride is also a potent pulmonary vasodilator by activating Kv channels and blocking voltage-gated, receptor-operated and store-operated Ca 2+ channels. Halofuginone hydrochloride has anti-malaria, anti-inflammatory, anti-cancer, anti-fibrosis effects .
2
2 Cited Publications
Cat. No.: HY-78349
CAS No.: 607737-87-1
Target:
Research Areas:
A 77-01 is a potent inhibitor of transforming growth factor (TGF)-β type I receptor superfamily activin-like kinase ALK5 with an IC50 of 25 nM .
2
2 Cited Publications
Cat. No.: HY-P72454
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: TGFBR1; Serine/Threonine-Protein Kinase Receptor R4; Prev. ESS1; Activin Receptor-Like Kinase 5; Prev. MSSE; TbetaR-I; ALK-5; TGFR-1; ALK5; SKR4; Transforming Growth Factor-Beta Receptor type I; Multiple Self-Healing Squamous Epithelioma; TGF-Beta Recepto
Species:
Mouse
Source:
HEK293
1
1 Cited Publications
Research Areas:
ODN 2216 is a type A CpG oligodeoxynucleotide vaccine adjuvant and a TLR9 agonist. ODN 2216 interacts with TLR9 in the lysosomes of CD4 + T cells and activates feedback-dependent signaling pathways. ODN 2216 induces the production of type I interferons, IL-6 and TGF-β via the IRAK4/IRF7 axis, while increasing intracellular ATP levels. ODN 2216 not only induces the differentiation of CD4 + T cells into anti-inflammatory Th3-like regulatory phenotypes to inhibit autologous proliferation, but also enhances the specific CD8 + T cell-mediated cytotoxicity against Mammaglobin-A in breast cancer cells. ODN 2216 is widely used in studies related to breast cancer and systemic lupus erythematosus .
1
1 Cited Publications
Cat. No.: HY-150741C
Purity: 97.92%
Target:
Research Areas:
ODN 2216 sodium is a type A CpG oligodeoxynucleotide vaccine adjuvant and a TLR9 agonist. ODN 2216 sodium interacts with TLR9 in the lysosomes of CD4 + T cells and activates feedback-dependent signaling pathways. ODN 2216 sodium induces the production of type I interferons, IL-6 and TGF-β via the IRAK4/IRF7 axis, while increasing intracellular ATP levels. ODN 2216 sodium not only induces the differentiation of CD4 + T cells into anti-inflammatory Th3-like regulatory phenotypes to inhibit autologous proliferation, but also enhances the specific CD8 + T cell-mediated cytotoxicity against Mammaglobin-A in breast cancer cells. ODN 2216 sodium is widely used in studies related to breast cancer and systemic lupus erythematosus .
1
1 Cited Publications
Target:
Research Areas:
TGFβ-IN-5 is a type I transforming growth factor-β receptor (TGF-β R1) kinase inhibitor with an IC50 value of 0.0485 μM. TGFβ-IN-5 reverses the effect of TGF-β-mediated cell activation on the expression of fibrosis-related genes. TGFβ-IN-5 can be used in the research of fibroproliferative diseases .
1
1 Cited Publications
Cat. No.: HY-P78525
Purity: ≥ 95%, as determined by Bis-Tris PAGE.
Synonyms: TGFBR1; Serine/Threonine-Protein Kinase Receptor R4; Prev. ESS1; Activin Receptor-Like Kinase 5; Prev. MSSE; TbetaR-I; ALK-5; TGFR-1; ALK5; SKR4; Transforming Growth Factor-Beta Receptor type I; Multiple Self-Healing Squamous Epithelioma; TGF-Beta Recepto
Species:
Human
Source:
HEK293
Target:
Research Areas:
BIBF0775 is a potent and selective transforming growth factor β (TGFβ) type I receptor (Alk5) inhibitor with an IC50 of 34 nM.
Cat. No.: HY-N2441
CAS No.: 74805-90-6
Category:
Ophiopogon japonicus (L. f.) Ker-Gawl. Liliaceae Flavonoids Phenols Polyphenols Plants Disease Research Fields Inflammation/Immunology Other Flavonoids
Target:
Cat. No.: HY-P3136
CAS No.: 25849-90-5
Synonyms: TRV120055
Target:
Research Areas:
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
